Related Experiment Video
Updated: May 12, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Intravesical chemotherapy]
1UO Complessa di Urologia Istituto di Clinica Urologica Luciano Giuliani, IRCCS Azienda Osp. Universitaria San Martino - IST, Genova - Italy. antoniocurotto@gmail.com
Urologia
|April 6, 2013
Summary
Bladder cancer treatment costs are rising, necessitating a focus on high-risk patients. Rationalizing intravesical therapies and perioperative chemotherapy is crucial for cost-effectiveness in bladder cancer care.
Area of Science:
- Urology
- Oncology
- Health Economics
Context:
- Bladder cancer incidence and treatment costs are increasing.
- Therapeutic advances in bladder cancer care have escalated expenses for all stakeholders.
- Intravesical treatment for non-muscle invasive bladder tumors is a significant cost driver.
Purpose:
- To critically evaluate current bladder cancer treatment strategies.
- To emphasize the need for rationalizing therapeutic schedules.
- To redirect research focus towards high-risk bladder cancer.
Summary:
- This perspective critically examines gemcitabine use, the cost-effectiveness of perioperative chemotherapy in high-risk patients, and the optimization of intravesical treatments.
- It highlights the financial burden of bladder cancer care and the need for strategic resource allocation.
- The authors advocate for focusing research on high-risk bladder cancers due to their recurrence and progression potential.
Impact:
- Provides critical insights into optimizing bladder cancer treatment costs.
- Guides healthcare providers and payers in making informed decisions regarding therapeutic interventions.
- Encourages a shift in research priorities towards managing aggressive bladder cancer subtypes effectively.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...